A Liquid Chromatographic Electrochemical Assay for S-2-(3-Aminopropylamino) Ethylphosphorothioate (WR2721) in Human Plasma

Abstract

A liquid chromatographic electrochemical method for the determination of the radioprotective drug WR2721 in human plasma has been developed. This method includes the use of a Hg/Au electrochemical detector for the direct measurement of WR2721 concentration. An analog of WR2721, S-3-{4-aminobutylamino} propylphosphorothioate (WR80855) is the internal standard. The retention times for WR2721 and WR80855 are approximately 4.5 and 9 minutes, respectively. WR1065, the free sulfhydryl metabolite of WR2721, is retained on the column under the described chromatographic conditions and therefore does not interefere with the determination of the parent drug. With modification of the mobile phase WR1065 is eluted from the column at a retention time of approximately 20 minutes. This method has good linearity, precision and accuracy, and is free from interference from endogenous plasma substances. Preliminary results showing the applicability of this method to human pharmacokinetic studies and to investigating the enzymatic hydrolysis of WR2721 are presented.     

Measurement Of Ethiofos (Wr 2721) In Plasma: Preliminary Pharmaco-Kinetics in the Beagle

Abstract

A specific, sensitive high performance liquid Chromatographie method for ethiofos [S-2-(3-aminopropylamino)ethyl phosphorothioate, WR 2721, I] in plasma is described. The detection limit is 0.05 (μg/mL (0.23 (μM). Application of the method to the development of pharma-cokinetic parameters following IV administration of the drug to beagle dogs is demonstrated. Presented are pharmacokinetics of unchanged drug in plasma on 10-min constant-rate infusion of 150 mg/kg to two dogs, two studies in each dog. Following the cessation of drug infusion the plasma concentration versus time profile was best described by a two-compartment pharmacokinetic model. Mean pharmacokinetic parameters were: terminal elimination half-life=16.0 min, volume of central compartment=120 mL/kg and clearance=11.0 mL/min/kg.     

Measurement of S-2-(3-Aminopropylamino)ethanethiol (WR1065) in Blood and Tissues

Abstract

A procedure for the analysis of blood and tissue specimens for WR1065, the dephosphorylated metabolite of the radioprotective drug WR2721, has been developed. The method includes the use of a perchloric acid/EDTA extraction step at 0°C followed by chromatographic analysis using a mercury/gold thin film electrochemical detection liquid chromatography system. The extraction technique was designed to assure the stability of both WR1065 and any WR2721 present in blood or tissues. Using the described chromatography conditions and an analog of WR1065, 3-(4-aminopropylamino)propanethiol (WR251833), as an internal standard the respective retention times of these two compounds are 6.2 and 8.3 minutes. Experiments showing the applicability of this method to pharmacokinetic studies of WR2721 and WR1065 and to investigation of the kinetics of WR2721 hydrolysis in biological fluids such as stomach juice are described.     

An Optimized Method for the quantitation of Carboxyamidotriazole (CAI) in Human Plasma with Solid Phase Extraction and reversed Phase HPLC

Abstract

The anticancer agent CAI was quantitated from human plasma using a C-18 column with a mobile phase consisting of acetonitrile and water (each containing 0.01M ammonium acetate) pumped over a gradient at a flow rate of 1.0 mL min. The detection of CAI and the internal standard, harmine, was accomplished using a photodiode-array detector set at 264 and 323 nm, respectively. The chromatographic run time was 17.5 minutes. The plasma samples were prepared for HPLC analysis using a C-18 solid phase extraction procedure. Two calibration curves were prepared. and the assay was shown to be linear in the concentration range of 0.02 to 0.5 μg/mL for the low curve and 0.25 to 10.0 μg/mL for the high curve, with average correlation coefficients of 0.9933 and 0.9938, respectively. Intra-assay and inter-assay imprecisions were less than 10.0% with an error of accuracy of less than 11.0%. The assay was reproducible with the sensitivity needed for the prediction of CAI levels in the plasma of cancer patients.     

Rapid and Sensitive Hplc Determination of Ranitidine in Plasma. Application to Pharmacokinetics Study

Abstract

A rapid and sensitive reversed-phase high-performance liquid chrormatography (RP-HPLC) method for the separation and quantification of the H₂-receptor antagonist drug ranitidine in human plasma is described.

The extraction of ranitidine from plasma by an organic solvent was eliminated in this method. Instead, the pre-chromatography isolation of the drug was done by adding approximately 50 mg of zinc sulfate and 200 μL of acetonitrile in 1.0 mL of plasma. A short column packed with pH-stable (1–13) reversed phase PLRP-S^TM particles was used with an isocratic elution of 5.0mM dibasic potassium phosphate plus 0.50mM tetraethyl ammonium hydroxide/ acetonitrile, 80:20 (v/v). The ranitidine was monitored at 315 nm and 0.20 to 0.002 absorption units full scale (AUFS). The completion time of the assay was less than 15 minutes and had a limit of detection of 1.0 ng/mL for a 100-μL injection volume.

After an oral dose of 150 mg of ranitidine, plasma samples were collected at several time points and were analyzed by using this method to determine various pharmacokinetic parameters.     

A Method for the Measurement of total Drug Convertible to Cysteamine: Application to Pharmacokinetic Experiments with Ethiofos

Abstract

An analytical method has been developed for the quantification of cysteamine (2-aminoethanethiol) in plasma. A reductive sample pretreatment is used to convert disulfide-bound cysteamine to the free thiol which is subsequently separated by HPLC and detected by electrochemical detection (LCEC). The method was developed to follow drug disposition after administration of ethiofos (WR-2721, S-2-(3-aminopropylamino) ethyl phosphorothioic acid) and WR-1065 (2-(3-aminopropylamino)ethanethiol). Standard calibration curves were linear over the range 0.01- to 25.0 /μg/mL (0.130-324 μM) and a minimum detectable quantity of 0.01 μg/mL was calculated at a signal-to-noise ratio of 3. Assay precision over the same range averaged 2% (coefficient of variation) and relative recovery, used as a measure of accuracy, was 100Z. Stability of cysteamine in plasma, relative to an internal standard (2-aminopropanethiol, WR-186) was good; stored samples were found to contain an average of 94.6 ± 10.4z of the original cysteamine concentration following 28 days at -75 °C.

This method was successfully applied in dosing experiments with rhesus monkeys in which ethiofos was administered into the cephalic vein (IV), portal vein (P) and duodenum. In IV experiments total VR-1065 plasma concentrations greatly exceeded total cysteamine concentrations. While results indicate formation of free and bound cysteamine is not a major metabolic pathway of ments total VR-1065 plasma concentrations greatly exceeded total cysteamine concentrations. While results indicate formation of free and bound cysteamine is not a major metabolic pathway of ethiofos, increased levels of bound cysteamine were observed.     

Kinetic Spectrofluorometric Determination of Thioctic Acid in Bulk and Pharmaceutical Preparations via its Oxidation with Cerium(IV)

A highly simple and sensitive kinetic spectrofluorometric method was developed for the determination of thioctic acid. The method is based on the oxidation of the studied drug with cerium(IV) ammonium sulfate in acidic medium. The fluorescence of the produced Ce(III) was measured at 365 nm after excitation at 255 nm. The different experimental parameters affecting the development and stability of the reaction product were carefully studied and optimized. The method is applicable over the concentration range of 0.02 to 0.12 μg/mL with a detection limit of 6.06 × 10^?3 μg/mL and a quantification limit of 0.02 μg/mL. The method was successfully applied for the assay of the studied drug in pharmaceutical formulations. The results obtained were in good agreement with those obtained with the reference method.     

Simultaneous quantification of propofol,ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats

The combination of propofol, ketamine and rocuronium can be used for anesthesia of ventilated rats. However, reliable pharmacokinetic models of these drugs have yet to be developed in rats, and consequently optimal infusion strategies are also unknown. Development of pharmacokinetic models requires repeated measurements of drug concentrations. In small animals, samples must be tiny to avoid excessing blood extraction. We therefore developed a drug assay system using high‐performance liquid chromatography coupled with quadrupole mass spectrometry that simultaneously determines the concentration of all three drugs in just 10 μL rat plasma. We established a plasma extraction protocol, using acetonitrile as the precipitating reagent. Calibration curves were linear with R² = 0.99 for each drug. Mean recovery from plasma was 91–93% for propofol, 89–93% for ketamine and 90–92% for rocuronium. The assay proved to be accurate for propofol 4.1–8.3%, ketamine 1.9–7.8% and rocuronium ?3.6–4.7% relative error. The assay was also precise; the intra‐day precisions were propofol 2.0–4.0%, ketamine 2.7–2.9% and rocuronium 2.9–3.3% relative standard deviation. Finally, the method was successfully applied to measurement the three drugs in rat plasma samples. Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.     

Simple HPLC‐UV for the quantification of a new leishmanicidal candidate (E)‐1‐4(trifluoromethyl) benzylidene)‐5‐(2‐4‐dichlorozoyl) carbonylhydrazine (LASSBio‐1736) in rat plasma for pharmacokinetics assessment

In this study, a sensitive HPLC‐UV assay was developed and validated for the determination of LASSBio‐1736 in rat plasma with sodium diclofenac as internal standard (IS). Liquid–liquid extraction using acetonitrile was employed to extract LASSBio‐1736 and IS from 100 μL of plasma previously basified with NaOH 0.1 M. Chromatographic separation was carried on Waters Spherisorb^®S5 ODS2 C₁₈ column (150 × 4.6 mm, 5 μm) using an isocratic mobile phase composed by water with triethylamine 0.3% (pH 4), methanol and acetonitrile grade (45:15:40, v/v/v) at a flow rate of 1 mL/min. Both LASSBio‐1736 and IS were eluted at 4.2 and 5 min, respectively, with a total run time of 8 min only. The lower limit of quantification was 0.2 μg/mL and linearity between 0.2 and 4 μg/mL was obtained, with an R² > 0.99. The accuracy of the method was >90.5%. The relative standard deviations intra and interday were <6.19 and <7.83%, respectively. The method showed the sensitivity, linearity, precision, accuracy and selectivity required to quantify LASSBio‐1736 in preclinical pharmacokinetic studies according to the criteria established by the US Food and Drug Administration and European Medicines Agency. Copyright © 2016 John Wiley & Sons, Ltd.     

Determination of Suramin in Plasma and Urine by Ion-Paired Reverse-Phase High-Performance Liquid Chromatography

Abstract

A high-pressure liquid chromatographic (HPLC) assay has been developed for the quantification of the anti-viral drug suramin (SUR) in human plasma and urine. This assay is simple and accurate, using an isocratic mobile phase in a reverse-phase ion-pairing mode.

This assay was developed for the determination of high levels of suramin in the urine and plasma of patients being treated for the acquired immunodefficiency Syndrome (AIDS). The limit of detection of this assay was 0.25 μg/mL. Congo red (CR) was used as the internal standard with a retention time of 5.9 min, while suramin had a retention time of 13 min.     

New chemical constituents from the Piper betle Linn. (Piperaceae)

The phytochemical investigation of chloroform extract from Piper betle var. haldia, Piperaceae, leaves has resulted in the isolation of two new chemical constituents which were identified as 1-n-dodecanyloxy resorcinol (H1) and desmethylenesqualenyl deoxy-cepharadione-A (H4), on the basis of spectroscopic data 1D NMR (¹H and ¹³C) and 2D NMR (¹H-¹H COSY and HMBC) as well as ESI-MS, FT-IR and HR-ESI-MS analyses. Compounds H1 and H4 showed excellent antioxidant DPPH free radical scavenging activity with IC₅₀ values of 7.14 μg/mL and 8.08 μg/mL compared to ascorbic acid as a standard antioxidant drug with IC₅₀ value of 2.52 μg/mL, respectively. Evaluation of cytotoxic activity against human hepatoma cell line (PLC-PRF-5) showed moderate effect with the GI₅₀ values of 35.12 μg/mL for H1, 31.01 μg/mL for H4, compared to Doxorubicin^® as a standard cytotoxic drug with GI₅₀ value of 18.80 μg/mL.     

Therapeutic Drug Monitoring of Suramin and Protein Binding

Abstract

A liquid chromatographic method of suramin has been used for the determination of the polysulfonated naphtylurea in both plasma and plasma filtrate from prostate cancer patients treated with the drug. The chromatographic system is based on the use of tetrabutylammonium bromide as an ion-pairing agent, while UV detection at 237 nm and 313 nm is applied. The sample pretreatment is a simple deproteination step by an organic solvent. The same counter-ion as used in the phase system is added in order to increase the recovery of the almost complete protein-bound suramin. The minimum detectable concentration in plasma is ca. 20 ng/mL at 237 nm, in plasma filtrate 10 ng/mL at 237 nm.

The method was routinely applied in plasma level guided treatment of prostate cancer patients with suramin, as well as in protein binding studies. The data of the study demonstrated the necessity of therapeutic drug monitoring in suramin treatment: development of severe, irreversible toxicity could be prevented owing to timed withdrawal of suramin administration when total drug levels were beyond 300 μg/mL. Data of protein binding studies explained in part the development of severe toxicity associated with plasma levels beyond 300–350 μg/mL: at that point free fraction of suramin sharply increases from 500 ng/mL at a total plasma level of 500 μg/mL to 10 μg/mL at a total plasma concentration of 1000 μg/mL, which corresponds with a twenty-fold dose increase (2000%).     

A Novel Molecule: 1-(2,6 Dichlorobenzyl)-4-(2-(2-4-hydroxybenzylidene)hydrazinyl)pyridinium Chloride and its Interaction with DNA

Herein, a novel pyridine derivative, 1-(2,6 dichlorobenzyl)-4-(2-(2-4-hydroxybenzylidene)hydrazinyl)-pyridinium chloride (DHPC), was synthesized as a candidate drug molecule. Interaction of DHPC with DNA was used to explore its effect on DNA via Differential Pulse Voltammetry, Cyclic Voltammetry, and Electrochemical Impedance Spectroscopy. We demonstrated that oxidation signal of guanine bases of DNA decreased significantly while that of DHPC increased after its interaction with one another. Our candidate drug molecule exhibits LOD and LOQ, e.g., 1.5 μg/mL and 4.9 μg/mL, respectively. Toxicity effect value for DHPC (S%) was calculated as %31, demonstrating the candidate drug molecule's toxic effect on DNA.     

Design,synthesis and biological evaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl)piperazin-1-yl)acetyl)indolin-2-one and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin-2-one analogues as novel anti-tubercular agents

A series of thirty-six novel 5-(2-(4-(benzo[d]isoxazol-3-yl)piperazin-1-yl)acetyl)indolin-2-one and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin-2-one analogues were synthesized, characterized and screened for their in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv strain. These compounds exhibited minimum inhibitory concentration between 1.56 and 50 μg/mL. Among these derivatives, compounds 10c, 10d, 10j, 10o and 10v (MIC 6.25 μg/mL) displayed moderate activity, while compounds 10e, 10l, 10q, 10w,10x, 12d, 12e and 12i (MIC 3.12 μg/mL) showed good anti-tubercular activity and compounds 10f, 10k, 10p, 10r, 12f, 12j and 12k (MIC 1.56 μg/mL) exhibited excellent anti-tubercular activity. In addition, MTT assay was accomplished on the active analogues of the series against mouse macrophage (RAW 264.7) cells to evaluate the cytotoxic effect of the newly synthesized compounds and selectivity index of the compounds was determined.     

Determination of Ibafloxacin,A New Quinolone Antibacterial,in Human and Dog Plasma and Urine by High Performance Liquid Chromatography

Abstract

A simple, selective and sensitive high performance liquid chromatographic method has been developed for quantifying plasma and urine ibafloxacin levels in humans and dogs.

Sample pretreatment is done by incorporation of an internal standard (IS) followed by a single step chloroform extraction. Samples are then chromatographed by reverse phase chromatography with UV detection. The lowest quantifiable concentration is 0.1 μg ibafloxacin/mL with a 1 mL sample. The assay was linear over the range of 0.1–50 μg/mL.     

A Novel Method for the Quantitation of Warfarin and its Metabolites in Plasma

Abstract

A procedure for the rapid, quantitative recovery of warfarin and its metabolites (diastereoisomeric alcohol, 4′-, 6-, 7-, 8-benzylic-hydroxywarfarin and dehydrowarfarin) from plasma with Sep-Pak C₁₈ cartridges has been developed. A solution of warfarin and its metabolites in plasma was acidified with NH₄OAc buffer (pH 4.85), adsorbed on the Sep-Pak C₁₈ resin, washed free of polar constituents and eluted with methanol. Dilution of the eluate with buffer followed by gradient high performance liquid chromatography permitted accurate quantitation of the desired compounds when detected at 313 nm. The recovery of warfarin and each metabolite was greater than 95% over an investigated range of 0.5–10.0 μg/ml of plasma and the limit of quantitation by the assay was 0.1 μg/ml of plasma. For more rapid quantitation of warfarin, without simultaneous analysis of metabolites, the chromatographic parameters were modified so that elution of warfarin occurred within 13 minutes, and the sensitivity of the assay increased to 0.03 μg of warfarin/ml of plasma. The quantitative recovery of warfarin and its metabolites coupled with the chromatographic versatility of the method make it ideally suited for either detailed pharmacokinetic studies or routine plasma analysis of warfarin.     

Spectrophotometric Determination of Metoclopramide and Oxybuprocaine Through Ion Pair Formation with Thiocyanate and Molybdenum(V) or Cobalt(II)

Abstract

Two spectrophotometric methods involve the formation of two different ion pairs between the drug and inorganic complexes, Mo(V) and Co(II) thiocyanates followed by their extraction with dichlor?methane and o-nitrotoluene, respectively. The optimum conditions for the ion pair formation are established. The methods permit the determination of metoclopramide and oxybuprocaine hydrochlorides over a concentration range of 1-20 μg ml^?1 and 20–240 μg ml^?1 using Mo(V) and Co(II) thiocyanates, respectively. Molar ratio of drug to Mo(V) or Co(II) indicates a 2:1 ratio for the two drugs studied in the presence of excess thiocyanate concentration. Results of the analysis of drug substances and their dosage forms by the proposed methods are in good agreement with those obtained by the official methods.     

Spectrophotometic Determination Of Tin In Steels With2-(5-Nltro-2-Pyridylazo)-5-[N-n-Propyl-N-(3-Sulfopropyl)Amino]phenol

ABSTRACT

A highly sensitive azo dye, 2-(5-nitro-2-pyridylazo)-5-[N-n-propyl-N-(3-sulfopropyl)amino]phenol (Nitro-PAPS), is used as a colorimetric reagent for the determination of tin(IV) content. Nitro-PAPS reacts with tin(IV) to form a water-soluble complex in 1.0 M acetic acid. Full color development is attained within 5 minutes, and maintains constant absorbance for at least 24 hours. The apparent molar absorptivity is 7.7 x 10⁴ dm³ mol^?1 cm^?1 at a maximum wavelength of 580 ran. Beer's law is obeyed for tin(IV) in the range of 0-1.2 μg ml^?1. The proposed method is successfully applied to the determination of trace amounts of tin in steels.     

Determination of carboplatin in canine plasma by high‐performance liquid chromatography

Carboplatin is an antineoplastic drug administered to treat different tumoral conditions in canine oncology. The objective of this study was to validate a high‐performance chromatographic (HPLC) method which could be applied in canine pharmacokinetic studies. Following ultrafiltration using a Centrifree device, standards, quality controls and plasma samples were separated by isocratic reversed‐phase HPLC on an Inertsil ODS‐2 (250 × 4.6 mm i.d.) analytical column and quantified using UV detection at 220 nm. The mobile phase was potassium phosphate (pH 4.5), with a flow‐rate of 1.0 mL/min. The procedure produced a linear curve (r² > 0.999) over the concentration range 1–200 μg/mL. The lower limit of quantification was 1 μg/mL. The intra‐assay and inter‐assay precision was ～90%. The overall recovery was ～90%. The method was illustrated with a preliminary pharmacokinetic analysis on nine dogs treated with carboplatin at our hospital. Carboplatin disposition followed a monocompartmental structure in dogs and was characterized by a short half‐life (50 min). Copyright © 2009 John Wiley & Sons, Ltd.     

Ternary ion-association complexes between the indium(III) - 4-(2-pyridylazo)resorcinol anionic chelate and some tetrazolium cations

Complex formation and liquid-liquid extraction were studied in systems containing indium(III), 4-(2-pyridylazo)resorcinol (PAR), tetrazolium salt (TZS), water and chloroform. Two different TZS were used: 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). The optimum conditions for extraction of In(III) as a ternary complex, (TT⁺)[In(PAR)₂] or (MTT⁺)[In(PAR)₂], were found: pH, extraction time, concentration of PAR and concentration of TZS. The constants of extraction (K_ex), constants of association (β), constants of distribution (K_D) and recovery factors (R%) were determined. The apparent molar absorptivities in chloroform were calculated to be ɛ′₅₂₀=6.6×10⁴ L mol⁻¹ cm⁻¹ and ɛ′₅₁₅=7.1×10⁴ L mol⁻¹ cm⁻¹ for the systems with TTC (I) and MTT (II), respectively. Beer’s law was obeyed for In(III) concentrations up to 3.4 μg mL⁻¹ in both the cases. The limits of detection (LOD=0.07 μg mL⁻¹ I and LOD=0.12 μg mL⁻¹ II), limits of quantification (LOQ=0.24 μg mL⁻¹ I and LOQ=0.41 μg mL⁻¹ II) and Sandell’s sensitivities (SS) were estimated as well.